Age-related macular degeneration

This study tests an oral drug called STL303 for geographic atrophy, a form of dry age-related macular degeneration that causes a blind spot in central vision. About 300 adults aged 60 and older will receive either STL303 or a placebo pill for up to 2 years. The goal is to see if …

This study tests a single injection into the eye of a new drug (SAR446597) for people with geographic atrophy, a progressive form of age-related macular degeneration that causes vision loss. About 104 participants aged 60 and older will be followed for 2 years, with an optional 3…

This study tests a new medicine called tiespectus (EYE201) for wet age-related macular degeneration, a leading cause of vision loss. About 960 people will receive either tiespectus or the standard treatment aflibercept via eye injections. The goal is to see if tiespectus can impr…

This phase 3 trial tests two injectable drugs, pozelimab and cemdisiran, alone or together, to slow the growth of geographic atrophy—an advanced form of dry age-related macular degeneration that causes central vision loss. About 975 participants will receive either the drugs or a…

This study tests a cell therapy called OpRegen for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. About 60 participants will receive a one-time injection of retinal cells under the retina during eye surgery. The m…

This study follows people who already received an eye injection of JNJ-81201887 or a sham in earlier studies for geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The goal is to check long-term safety, including side effects and eye …

This study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots in people with geographic atrophy, an advanced form of dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the…

This Phase 2 trial tests FWY003, an experimental drug, in 272 people with geographic atrophy (a form of advanced age-related macular degeneration). The goal is to see if different doses can slow the growth of damaged areas in the eye and preserve vision. Participants receive eith…

This early-stage study tests a stem cell therapy called ASP7317 for people with geographic atrophy, the advanced form of dry age-related macular degeneration that causes central vision loss. The treatment involves injecting special cells under the retina to replace damaged ones. …

This study tests an experimental drug called ADX-038 in 240 people with geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss of a key…

This study tests a device that delivers tiny electrical pulses through the eyelid to the back of the eye. The goal is to see if it can safely slow vision loss or improve sight in people with intermediate to advanced dry age-related macular degeneration. One hundred participants w…

This study tests whether dapagliflozin, a drug used for diabetes, can slow the progression of geographic atrophy—an advanced form of dry age-related macular degeneration that causes blind spots. About 70 adults aged 50 and older with this condition will take the drug for 12 month…

This study tests whether GAL-101 eye drops can slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes blind spots. About 110 adults aged 55 and older with early-stage atrophy will use the drops or a placebo daily for up to two years…

This early-stage study tests a new treatment called C.001 for people with retinal diseases that cause vision loss, such as geographic atrophy and Stargardt disease. The treatment is given as a single injection into the eye. The main goal is to check if it is safe, and researchers…

This study tests whether a targeted laser treatment, called photothermal therapy, can slow the progression of intermediate age-related macular degeneration (AMD). About 240 people aged 60–90 with intermediate AMD will receive either the laser or a sham procedure. The main goal is…

This early-stage trial tests whether transplanting lab-grown retinal cells into the eye is safe for people with geographic atrophy from dry age-related macular degeneration. Twenty participants aged 55 and older will receive a transplant of their own reprogrammed cells into one e…

This study tests a new gene therapy (VV-14295) given as an injection into the eye for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The goal is to see if it is safe and can slow the growth of these blind spots. Ab…

This study tests a new drug called tiespectus (MK-8748) against the current standard treatment, aflibercept, for people with wet age-related macular degeneration (AMD). About 960 participants will receive injections into the eye and be followed for a year to see if tiespectus can…

This study tests if a device that delivers mild electrical pulses to the eye (transcorneal electrical stimulation) can safely slow the progression of geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 70 people aged 60 and olde…

This study tests a new medicine called ABBV-6628 for people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 66 adults aged 50 and older will receive eye injections of the study drug or an approved treatment (SYFOVRE…

This study tests whether injecting a person's own bone marrow stem cells into or near the eye can help treat various retinal and optic nerve diseases, including age-related macular degeneration, retinitis pigmentosa, and glaucoma. Participants receive stem cell injections via dif…

This Phase 2 trial tests whether adding APL-3007 to the existing drug Syfovre (pegcetacoplan) can better slow geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. About 240 adults aged 60 and older with the condition will receive e…

This study tests a biodegradable eye implant called TO-O-1007 for geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The implant slowly releases medication over 6 months to slow disease progression. About 31 adults aged 50 and old…

This study looks at 100 people with wet age-related macular degeneration (AMD) who have been getting regular eye injections with older drugs. They will switch to a newer drug called faricimab. The goal is to see if faricimab can extend the time between injections, meaning fewer t…

This study tests a single injection of CTx001 gene therapy into the eye for people with geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. The trial involves 75 participants and will monitor safety and whether the treatment can slow d…

This study tests the drug faricimab (Vabysmo) in 100 people aged 50+ with wet age-related macular degeneration who have a specific type of harmful material under their retina. The goal is to see if the drug can clear that material by week 16. Participants receive injections into …

This early-stage trial tests an experimental drug called BBC1501, given as an injection into the eye, for people with wet age-related macular degeneration (nAMD). The main goal is to check safety and tolerability in 18 volunteers aged 50 and older who have already received standa…

This study tests a small telescope-like implant called SING IMT™ for people with advanced age-related macular degeneration (AMD) who have poor central vision in both eyes. The device is placed inside the eye during surgery, either replacing or sitting in front of the existing len…

This Phase 3 trial tests faricimab (Vabysmo) in 50 people with a type of age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if a personalized treat-and-extend schedule can keep the eye healthy while allowing longer breaks between i…

This study looks at how well a higher dose (8mg) of the drug Aflibercept (Eylea) works in the first two months for people with wet age-related macular degeneration, a leading cause of vision loss. Researchers will track fluid changes in the retina and vision improvements in 50 pa…

This study tests whether a 6-month online stationary cycling program can improve vision, physical function, and thinking skills in veterans aged 65-89 with intermediate age-related macular degeneration (AMD). Researchers will measure contrast sensitivity, night vision, and visual…

This study tests a small telescope-like implant placed inside the eye to improve vision in people with end-stage age-related macular degeneration (AMD). 76 participants aged 55 and older will receive the implant and be followed for 12 months. The goal is to see if the device safe…

This early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. About 68 participants will take either ABF-101 or a placebo to see if it is wel…

This study tests whether an oral drug called dimethyl fumarate (Tecfidera) can safely slow the growth of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss. About 90 adults aged 55–85 with geographic atrophy will take the drug for 12 m…

This study tests whether high-dose atorvastatin (a statin drug) can improve vision in people with intermediate age-related macular degeneration (AMD). Researchers will measure how quickly participants' eyes adjust to darkness and track changes in fatty deposits (drusen) in the re…

This study tests whether taking krill oil capsules daily for 3 months can reduce drusen (fatty deposits) in the eyes of people with early or intermediate dry age-related macular degeneration (AMD). 24 adults will receive either krill oil or a placebo. The main goal is to see if t…

This study tests whether taking a daily supplement of lutein, zeaxanthin, and fish oil for six months can improve thinking skills, eye health, and bone density in healthy adults. Researchers will enroll 80 people with low levels of a key eye pigment. Participants will take either…

This Phase 3 trial tests whether QA108 granules, a traditional Chinese medicine, can reduce drusen (fatty deposits) in the eyes of people with intermediate age-related macular degeneration. 400 participants will take the granules or a placebo for 24 weeks. The study aims to see i…

This study looks at whether a virtual reality maze test can measure how well people with age-related macular degeneration (AMD) see in dim light. It will compare results from this VR test with a standard dark adaptation test in older adults with early or intermediate AMD and in h…

This trial tests whether an artificial intelligence system called VeriSee can help doctors diagnose age-related macular degeneration and diabetic retinopathy from standard eye photos. The AI analyzes the images and provides instant results for the ophthalmologist to consider. Res…

This study tests whether an AI tool (VeriSee) can help doctors detect two common causes of vision loss—diabetic retinopathy and age-related macular degeneration—earlier than standard exams. About 4,300 adults with diabetes or aged 50+ will be randomly assigned to AI-assisted scre…

This study tests a special camera that takes detailed images of the retina using many wavelengths of light. Researchers hope it can find early signs of eye diseases like age-related macular degeneration, diabetic retinopathy, and glaucoma. About 1,000 adults in Melbourne, Austral…

This study tests a new device that uses special 'structured light' patterns to see if people with age-related macular degeneration (AMD) perceive them differently than those with healthy vision. The goal is to develop a test that can detect AMD earlier than current methods, befor…

This study is testing whether an AI system called DeepMSI AI can detect biomarkers of dry age-related macular degeneration (AMD) as accurately as experienced eye doctors. About 1,000 adults over 40, including those with and without AMD, will have their retinas imaged with a speci…

This study tests whether eating goji berries five days a week for six months can lower the risk of age-related macular degeneration (AMD) in people aged 65 to 95. Participants will eat 14 grams of goji berries or a fiber supplement and have their eye health, gut bacteria, and oth…

This trial tests whether a community-based screening program using advanced eye imaging (OCT, fundus photography, and pressure checks) can prevent vision loss from age-related macular degeneration, diabetic retinopathy, and glaucoma better than simple vision tests alone. About 60…

This study looks at whether disulfiram (Antabuse), a drug used for alcohol use disorder, can improve vision in people with retinal degeneration (like macular degeneration or retinitis pigmentosa). Researchers believe it may calm overactive cells in the retina. The study involves …

This study tests whether shifting text to healthier parts of the visual field can help people with age-related macular degeneration read faster and make fewer mistakes. About 108 participants with central vision loss will try two different text-remapping methods. The goal is to f…

This study looks at whether a visual rehabilitation program can ease anxiety and depression in people with advanced age-related macular degeneration (AMD). Twenty-two participants will attend five group sessions over 60 days, learning skills like coin recognition, using voice ass…

This early-phase trial tests whether a one-hour occupational therapy session—teaching strategies like better lighting, contrast, and organizational tools—can help people with age-related macular degeneration, diabetic retinopathy, or glaucoma manage their medications. Fifty parti…

This study tests whether a gentle electrical brain stimulation, called a-tDCS, can make reading training more effective for people with age-related or juvenile macular degeneration. About 30 participants will do six reading training sessions while receiving either real or fake st…

This study is creating a large collection of health information and biological samples (like blood, saliva, and eye tissue) from people with and without retinal diseases. Researchers aim to use this database to better understand conditions like age-related macular degeneration an…

This study aims to find out why 20-40% of people with wet age-related macular degeneration (AMD) don't respond well to standard anti-VEGF injections. Researchers will collect fluid from inside the eye of 117 patients and compare those who respond well to treatment with those who …

This study collects skin, hair, blood, urine, or saliva samples from people with certain eye diseases (like macular degeneration) and from healthy volunteers. Researchers will turn these samples into stem cells in the lab to study how the diseases develop and to test potential ne…

This study is the first time the experimental drug ARO-033 is being given to humans. Its main goal is to check the safety and tolerability of single and multiple doses in healthy adult volunteers. Researchers will also measure how the drug moves through the body. This is an early…

This study tests whether immune cells called monocytes from people with the atrophic form of age-related macular degeneration (AMD) survive longer on retinal cells than monocytes from healthy people. Researchers will collect blood samples from 80 participants, extract monocytes, …

This study observes 75 adults aged 55 and older with geographic atrophy (a late stage of age-related macular degeneration) to see how the condition progresses over a short time. Researchers will measure changes in eye structure and function, and explore links to genetics and life…

This study is testing whether a simple vision screening program in general practice can help detect vision loss early in adults over 70 who have at least one chronic condition. Participants will have three vision tests done by their GP or nurse, then visit a collaborating opticia…

This pilot study will test two new eye imaging devices (R1 and HighRes OCT) against a standard device in 97 adults with healthy eyes or eye diseases like macular degeneration and diabetic retinopathy. Researchers will compare image quality and how well key eye structures are seen…

This study investigates whether specialized visual function tests can detect early changes in people with early or intermediate age-related macular degeneration (AMD). Researchers will follow 120 adults with good visual acuity but early signs of AMD, using tests like microperimet…

This study follows 500 people with geographic atrophy, an advanced form of age-related macular degeneration that causes permanent vision loss. Participants receive avacincaptad pegol (IZERVAY) as part of their routine care. Researchers will collect data on treatment patterns, sid…

This study tracks eye pressure in 100 people receiving a larger-volume injection of Aflibercept (0.07mL) for macular diseases like age-related macular degeneration. Researchers measure pressure right after the injection and at several time points, then check for any nerve damage …

This study is following 1,500 adults aged 55 and older to learn how early age-related macular degeneration (AMD) turns into the advanced form that can cause vision loss. Researchers will use eye imaging, genetic tests, and other measurements to find clues that predict progression…

This study watches how vision changes over two years in 50 people aged 65-90 with geographic atrophy (a form of dry age-related macular degeneration) who are already taking the drug pegcetacoplan. Researchers will use a special vision test that maps light sensitivity near damaged…

This study looks at three drugs (bevacizumab, ranibizumab, and aflibercept) used to treat age-related macular degeneration (AMD), a leading cause of blindness in older adults. Researchers will analyze costs and quality of life for 600 patients in France to see which treatment off…

This study uses a special camera called an Adaptive Optics Scanning Laser Ophthalmoscope (AOSLO) to take very detailed pictures of the retina in people with inherited retinal diseases like retinitis pigmentosa. Researchers will measure how the light-sensitive cells in the eye cha…

This study is creating a large database of eye measurements from 3,000 people with inflammatory eye diseases like diabetic retinopathy and age-related macular degeneration. Researchers will use advanced imaging to collect detailed information from both the front and back of the e…

This study collects fluid and blood samples from 260 people with age-related macular degeneration, diabetic retinopathy, or retinal detachment, plus healthy controls. Researchers will analyze proteins in these samples to identify markers that could help diagnose or track these ey…

This study uses special cameras to take ultra-detailed pictures of the back of the eye in people with retinal diseases like macular degeneration and retinitis pigmentosa. Researchers aim to develop new ways to diagnose and track these conditions by measuring cell density and func…

This study uses a special camera called an adaptive optics scanning laser ophthalmoscope to take incredibly detailed pictures of the retina, the light-sensitive layer at the back of the eye. Researchers will compare images from healthy people and those with eye diseases like Star…

This study tests two simple ways to help people attend eye hospital appointments after being screened for age-related macular degeneration, diabetic retinopathy, or glaucoma. About 3,000 participants who need a follow-up visit will get either a text reminder, a home visit from a …

This study tests two advanced eye imaging techniques—central microperimetry and radial OCT—to see if they can more accurately measure the progression of geographic atrophy, a severe form of age-related macular degeneration that can lead to blindness. Researchers will follow 80 ad…

This study looks at whether repeated eye injections of bevacizumab, a drug used for diabetic eye disease and other conditions, might affect heart health. Researchers will measure certain enzymes in the blood that are linked to heart disease risk. The study includes 180 adults age…

This study is testing new eye exams to see if they can better track early age-related macular degeneration (AMD). Researchers will measure how quickly the eye adapts to darkness in 150 healthy volunteers and people with early AMD. The goal is to find reliable ways to measure dise…

This study enrolls 25 people with severe retinal diseases like retinitis pigmentosa and Stargardt disease to test new ways of measuring visual function. Researchers will evaluate how well participants can perform various vision tests, such as navigating obstacles or detecting lig…

This study is collecting eye images from 1,000 adults aged 50 and older, with or without age-related macular degeneration (AMD), from up to 25 countries. The goal is to create a high-quality, diverse dataset that researchers can use to train artificial intelligence (AI) to screen…

This study watches how early damage in age-related macular degeneration (AMD) grows over time. Researchers will use special eye scans to measure changes in the retina and see how they affect vision and daily life. The goal is to find better ways to detect and track the disease ea…

This observational study seeks to define a new concept called 'visual frailty' in people aged 60 and older with advanced age-related macular degeneration (AMD). Researchers will measure vision, reading ability, mental health, and daily function in 20 participants to develop a vis…

This study is for people with age-related macular degeneration who have bleeding under the retina. Researchers want to see if the type of abnormal blood vessel affects how well vision recovers after a gas bubble procedure to move the blood. About 60 participants will be followed …

This study looks at whether sinusitis (sinus infection) is common in people with wet age-related macular degeneration (AMD) who need many eye injections. Researchers will screen 200 participants for sinusitis and treat it if found. They will then check if sinusitis treatment redu…

This study tests a high-resolution imaging system to see tiny structures in the eye that routine tools cannot detect. Researchers will scan 1,200 people with various eye conditions and healthy volunteers. The goal is to better understand diseases like glaucoma, diabetes, and reti…